Browse by author
Lookup NU author(s): Dr Zelal Kharaba
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Copyright© Bentham Science Publishers; For any queries, please email at email@example.com.BACKGROUND: Metoclopramide is mainly metabolized by CYP2D6, CYP3A4, CYP2C19, and CYP1A2 enzymes, while cilostazol is also metabolized by CYP3A4, CYP2C19, and CYP1A2 enzymes. AIM: This study evaluates the effect of cilostazol on the pharmacokinetics of oral metoclopramide. METHODS: This was a randomized, two-phase cross-over pharmacokinetic study separated by a 4-week wash-out time period, 12 healthy non-smoking volunteers received metoclopramide 20 mg as a single oral dose and after 4 weeks, cilostazol 100 mg twice daily for 4 days then with metoclopramide 20 mg on test day. Serial blood samples were analyzed by using a validated high-performance liquid chromatography-ultraviolet method to determine maximum plasma drug concentration (Cmax), time to reach (Tmax), and area under the curve (AUC0-∞) of metoclopramide. RESULTS: Cilostazol increased the mean Cmax, AUC0-∞ and half-life (T1/2) of metoclopramide by 6%, 27% and by 0.79 %, respectively. In addition, Tmax of metoclopramide was delayed by cilostazol. CONCLUSION: The results showed delayed Tmax of metoclopramide by cilostazol, which could lead to the conclusion that cilostazol affects the absorption of metoclopramide. Both drugs when necessary to administer together must not be administered at the same time especially when given in gastroparesis patients.
Author(s): Kaukab I, Hussain Shah SN, Kharaba Z, Murtaza G, Saad AA, Ahmad S
Publication type: Article
Publication status: Published
Journal: Current Drug Metabolism
Online publication date: 01/09/2019
Acceptance date: 02/04/2019
ISSN (print): 1389-2002
ISSN (electronic): 1875-5453
Publisher: Bentham Science Publishers Ltd.
PubMed id: 31702486
Altmetrics provided by Altmetric